Objective: The aim of this study was to determine the prevalence of multiple sclerosis (MS) in the population of Csongrád County, Hungary (400,128 inhabitants) and to determine the functional status (based on the Expanded Disability Status Scale; EDSS) of the patients according to the clinical forms of the disease. Methods: The diagnosis was established with the aid of the Poser diagnostic criteria, and the degree of physical disability was determined using the Kurtzke EDSS. Results: In Csongrád County, the prevalence of MS is 62/100,000. The distribution of patients according to the clinical forms of MS was as follows: 15% had the benign form, 54% had relapsing-remitting MS, 20% had secondary chronic progressive MS and 11% had the primary chronic progressive form of MS. Sixty percent of relapsing-remitting MS patients had an EDSS score of 0–4 points and 33% had an EDSS score of 4.5–6.5 points. Conclusion: The distribution of patients according to the clinical forms of the disease in this representative population is comparable to results in other regions of the world.

Keywords:
Multiple sclerosis, Prevalence, Incidence, Clinical forms, Functional status
1.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;43:655–661.
2.
Pálffy G, Czopf J, Kuntár L, Gyódi É: Multiple sclerosis in Baranya County in Hungarians and in Gypsies; in Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological Update. Darmstadt, Leuchtturm/LTV, 1994, pp 274–278.
3.
Bencsik K, Rajda C, Klivényi P, Járdánházy T, Vécsei L: The prevalence of multiple sclerosis in the Hungarian city of Szeged. Acta Neurol Scand 1998;97:315–319.
4.
Kurtzke JF: MS epidemiology world wide. One view of current status. Acta Neurol Scand Suppl 1995;161:23–33.
5.
Poser CM: Notes on the epidemiology of multiple sclerosis. J Formos Med Assoc 1995;94:300–308.
6.
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983;13:227–231.
7.
Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, Fredrikson S, Gallo P, Grimaldi LM, Gronning M, et al: Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry 1994;57:897–902.
8.
Dean G: Epidemiology of multiple sclerosis. Neuroepidemiology 1984;3:58–73.
9.
Poser CM: The epidemiology of multiple sclerosis: A general overview. Ann Neurol 1994;36(suppl 2):180–193.
10.
Sadovnick AD: Genetic epidemiology of multiple sclerosis: A survey. Ann Neurol 1994;36(suppl 2):194–203.
11.
Sadovnick AD, Yee IML: Season of birth in multiple sclerosis. Acta Neurol Scand 1994;89:190–191.
12.
Ebers GC, Sadovnick AD, Risch NJ: A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995;377:150–151.
13.
Bansil S, Singhal BS, Ahuja GK, Ladiwala U, Behari M, Friede R, Cook SD: Comparison between multiple sclerosis in India and the United States: A case-control study. Neurology 1996;46:385–387.
14.
Benedikz J, Magnusson H, Guthmundsson G: Multiple sclerosis in Iceland, with observations on the alleged epidemic in the Faroe Islands. Ann Neurol 1994;36(suppl 2):175–179.
15.
Binzer M, Forsgren L, Holmgren G, Drugge U, Fredrikson S: Familial clustering of multiple sclerosis in a northern Swedish rural district. J Neurol Neurosurg Psychiatry 1994;57:497–499.
16.
Bronnum-Hansen H, Koch-Henriksen N, Hyllested K: Survival of patients with multiple sclerosis in Denmark: A nationwide, long-term epidemiologic survey. Neurology 1994;44:1901–1907.
17.
Bufill E, Blesa R, Galan I, Dean G: Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. J Neurol Neurosurg Psychiatry 1995;58:577–581.
18.
Cavalletti S, Merelli E, Cavazutti M, Guidetti D: Frequency of MS in the province of Modena, 1970–1990. Acta Neurol Scand 1994;90:377–381.
19.
Gonzalez O, Sotelo J: Is the frequency of multiple sclerosis increasing in Mexico? J Neurol Neurosurg Psychiatry 1995;59:528–530.
20.
Granieri E, Casetta I, Tola MR: Epidemiology of multiple sclerosis in Italy and in southern Europe. Acta Neurol Scand Suppl 1995;161:60–70.
21.
Ford HL, Gerry E, Airey CM, Vail A, Johnson MH, Williams DR: The prevalence of multiple sclerosis in the Leeds Health Authority. J Neurol Neurosurg Psychiatry 1998;64:605–610.
22.
Rothwell PM, Charlton D: High incidence and prevalence of multiple sclerosis in south east Scotland: Evidence of a genetic predisposition. J Neurol Neurosurg Psychiatry 1998;64:730–735.
23.
Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996;46:907–911.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.